Gros-30 Injection (Paclitaxel 30 mg/5 mL)

Gros-30 Injection contains Paclitaxel 30 mg/5 mL and is a prescription anticancer medicine manufactured by Emcure Pharmaceuticals Ltd. The pack shown is a single-dose vial intended for intravenous (I.V.) use only. Emcure’s current product/price documentation lists Gros 30 mg injection among its products.

Paclitaxel is a taxane chemotherapy medicine used as part of treatment plans for certain cancers. Because it can cause serious reactions, Gros-30 should only be administered by qualified healthcare professionals under the supervision of an experienced oncology team.

1. What is Gros-30 Injection?

Gros-30 Injection is an intravenous chemotherapy medicine containing paclitaxel, a member of the taxane class of anticancer drugs.

Paclitaxel works by affecting microtubules, structures that cancer cells need when they divide. It stabilizes these structures and prevents them from functioning normally during cell division. As a result, rapidly dividing cancer cells can become unable to continue multiplying and may eventually die.

Paclitaxel injection may be used in chemotherapy regimens for cancers such as:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• AIDS-related Kaposi’s sarcoma in appropriate clinical situations

The exact indication, treatment combination and schedule depend on the type and stage of cancer, previous treatment, laboratory results and the patient’s overall health. Approved uses can vary by formulation and country.

Gros-30 is not a medicine for self-treatment. It is an intravenous prescription chemotherapy product and must be administered in an appropriate medical setting with monitoring and emergency treatment facilities available.

2. Uses of Gros-30 Injection

Gros-30 Injection may be prescribed as part of chemotherapy treatment for selected cancers.

Common medically established uses of conventional paclitaxel injection include:

• Treatment of certain advanced ovarian cancers
• Treatment of selected breast cancers, including situations involving metastatic disease or specific adjuvant treatment plans
• Treatment of certain non-small cell lung cancers, commonly in combination with another chemotherapy medicine
• Second-line treatment of AIDS-related Kaposi’s sarcoma in appropriate patients

The choice of paclitaxel and its combination with other medicines is determined by an oncologist according to the individual cancer treatment plan.

This medicine should only be administered under the supervision of a qualified healthcare professional.

3. Benefits of Gros-30 Injection

Paclitaxel is an established chemotherapy medicine and may provide important benefits when appropriately incorporated into a cancer treatment regimen.

Potential benefits include:

• Helps slow or stop the growth of susceptible cancer cells
• Can be used as part of combination chemotherapy
• May help control certain advanced or metastatic cancers
• Can contribute to reduction of tumor burden in responsive cancers
• May support disease control and cancer treatment goals determined by the oncology team

The response to chemotherapy differs from person to person. Gros-30 should therefore not be considered a guaranteed cure, and treatment benefits should be evaluated by the treating oncologist.

4. How Does Gros-30 Injection Work?

The active ingredient in Gros-30 is paclitaxel.

Cancer cells need to divide continuously to grow and spread. During cell division, microtubules help move and organize cellular components. Paclitaxel binds to tubulin and promotes stabilization of microtubules, preventing their normal breakdown and remodeling.

This interferes with the normal process of cell division and can cause susceptible cancer cells to stop progressing through the cell cycle and die.

Because paclitaxel can also affect some healthy rapidly dividing cells, treatment may produce side effects such as reduced blood-cell counts, hair loss and gastrointestinal symptoms.

5. How to Take Gros-30 Injection

Gros-30 is not intended to be taken by mouth. The pack states that it is for I.V. use only.

General guidance includes:

• It should be administered as an intravenous infusion by trained healthcare professionals.
• The treatment schedule is determined by the oncologist.
• Do not attempt to inject or administer the medicine yourself.
• Do not change the treatment schedule or dose without medical advice.
• Blood counts and other clinical parameters may need to be monitored during treatment.
• Conventional paclitaxel formulations are commonly given with medical premedication to reduce the risk of hypersensitivity reactions.

The Gros-30 dosage is individualized and depends on factors such as the cancer being treated, treatment combination, body measurements, blood counts, liver function and previous reactions. Therefore, a specific dose or treatment schedule should only be determined by the treating oncologist.

If an appointment or scheduled infusion is missed, contact the oncology team rather than attempting to compensate with an additional dose.

6. Side Effects of Gros-30 Injection

Like all medicines, Gros-30 Injection may cause side effects, although not everyone experiences them.

Common Side Effects

Possible side effects of paclitaxel treatment include:

• Hair loss
• Reduced white blood cell or other blood-cell counts
• Nausea or vomiting
• Diarrhea
• Mouth sores or mucositis
• Muscle or joint pain
• Tiredness or weakness
• Peripheral neuropathy, such as tingling or numbness
• Changes in appetite
• Mild skin or nail changes
• Injection-related reactions

Some side effects can be temporary, while others may require treatment modification or closer monitoring.

Serious Side Effects

Paclitaxel can cause serious reactions requiring urgent medical attention, including:

• Severe allergic or hypersensitivity reactions
• Breathing difficulty or significant low blood pressure during administration
• Severe reduction in blood-cell counts and increased risk of infection
• Severe or worsening peripheral neuropathy
• Significant heart-rate or rhythm abnormalities
• Serious liver-related abnormalities
• Severe skin or other systemic reactions

Severe hypersensitivity reactions have been reported with paclitaxel, which is why administration should occur under appropriate medical supervision.

If side effects persist or become severe, contact your healthcare provider promptly.

7. Warnings and Precautions

Before treatment with Gros-30, tell the doctor about all existing medical conditions and medicines.

Pregnancy

Paclitaxel may cause fetal harm. Patients who are pregnant, planning pregnancy or who could become pregnant should discuss the risks and appropriate pregnancy-prevention measures with their healthcare team before treatment.

Breastfeeding

Breastfeeding may need to be avoided during paclitaxel treatment and for a period determined by the treating healthcare professional because the medicine may pose a risk to a breastfed infant.

Liver Disease

Paclitaxel is metabolized extensively by the liver. Patients with liver impairment may have an increased risk of toxicity, so liver function and treatment suitability should be assessed by the treating physician.

Kidney Disease

Kidney problems should be reported to the healthcare team. The overall treatment plan may require additional monitoring depending on the patient’s condition.

Heart Problems

Inform the doctor about previous heart disease, abnormal heart rhythm or other cardiovascular problems. Paclitaxel can occasionally affect heart rate or rhythm.

Elderly Patients

Older adults may require careful monitoring because age-related changes in organ function and other medical conditions can influence chemotherapy tolerance.

Allergies

Tell the medical team about any previous allergy or severe reaction to paclitaxel or related formulation ingredients. Severe hypersensitivity reactions are a recognized safety concern with conventional paclitaxel injection.

Driving and Operating Machinery

Patients may experience tiredness, dizziness or other treatment-related effects. Ask the healthcare professional whether driving or operating machinery is appropriate during treatment.

Alcohol

Alcohol may worsen certain treatment-related symptoms and may place additional strain on the liver. Discuss alcohol consumption with the oncology team rather than assuming it is safe.

8. Drug Interactions

Paclitaxel can interact with other medicines and may also affect or be affected by medicines used as part of chemotherapy.

Tell the doctor about:

• Prescription medicines
• Over-the-counter medicines
• Other chemotherapy medicines
• Antibiotics or antifungal medicines
• Medicines affecting liver enzymes
• Vitamins and mineral supplements
• Herbal or traditional medicines

Some medicines can alter paclitaxel metabolism or increase the risk of adverse effects. Paclitaxel is also commonly used in combination with other anticancer medicines, so the complete treatment regimen must be reviewed by the oncology team.

Do not start, stop or change another medicine during chemotherapy without discussing it with the treating healthcare professional.

9. Storage Instructions

Storage should follow the manufacturer’s product information and the requirements of the healthcare facility.

General precautions include:

• Keep the vial in the recommended storage conditions.
• Protect the product from inappropriate heat, light or moisture as applicable.
• Keep medicines away from children.
• Do not use a vial after its expiry date.
• Healthcare professionals should inspect the product before administration and follow appropriate handling procedures for injectable chemotherapy medicines.

Because Gros-30 is an injectable chemotherapy product, patients should not attempt to store, prepare or administer it for personal use outside a suitable medical setting.

10. Gros-30 Injection Price

The Gros-30 Injection price can vary depending on the market, supplier, taxes, applicable pricing regulations and other commercial factors. Emcure’s published pricing documentation has listed GROS 30 MG INJECTION among its products.

Patients should verify the current price and product availability through an authorized healthcare provider or pharmacy. The medicine is a prescription chemotherapy product and should be obtained and administered only through appropriate medical channels.

11. Gros-30 Manufacturer

Gros-30 Injection is manufactured by Emcure Pharmaceuticals Ltd. The uploaded product pack identifies the brand as Gros-30, with paclitaxel listed at 30 mg/5 mL and the product marked for I.V. use only. Emcure’s official published product pricing documents also list Gros 30 mg injection.

12. Frequently Asked Questions

1. What is Gros-30 Injection used for?

Gros-30 contains paclitaxel and is used as part of chemotherapy for selected cancers, including certain breast, ovarian and non-small cell lung cancers and, in appropriate circumstances, AIDS-related Kaposi’s sarcoma. The exact use depends on the patient’s diagnosis and treatment plan.

2. How does Gros-30 work?

Gros-30 works through paclitaxel, which interferes with microtubules required for cell division. By stabilizing microtubules and disrupting normal cell division, paclitaxel can prevent susceptible cancer cells from continuing to multiply.

3. Is Gros-30 safe?

Paclitaxel can be an effective chemotherapy medicine when appropriately prescribed and monitored, but it can also cause serious adverse reactions. Severe hypersensitivity, reduced blood-cell counts and nerve-related effects are among important risks. It should only be administered under specialist medical supervision.

4. Can Gros-30 be used long term?

The duration of paclitaxel treatment depends on the type of cancer, response to therapy, treatment protocol and tolerance. It is not appropriate to decide independently how long treatment should continue. The oncologist will determine the number and timing of treatment cycles and may modify therapy according to laboratory results and side effects.

5. What happens if a scheduled Gros-30 dose is missed?

Gros-30 is administered by an oncology team, so a missed appointment should be discussed with the treating healthcare facility. Do not attempt to compensate for a missed infusion or arrange an additional dose yourself. The healthcare team will determine the safest timing for the next treatment.

6. Can Gros-30 be stopped suddenly?

Gros-30 is given in planned chemotherapy cycles rather than as a medicine that patients normally stop independently. If treatment needs to be delayed, changed or discontinued because of side effects, blood-count changes or other circumstances, the decision should be made by the treating oncologist.

7. Can Gros-30 be taken with food?

Gros-30 is an intravenous injection, not an oral medicine, so food does not determine how the injection itself is taken. However, patients receiving chemotherapy may receive specific dietary or medication advice from their healthcare team depending on their treatment and symptoms.

8. What are the common Gros-30 side effects?

Common paclitaxel-related side effects can include hair loss, reduced blood-cell counts, nausea, vomiting, diarrhea, muscle or joint pain, tiredness and peripheral neuropathy. Side effects vary between patients. Any severe, persistent or unusual symptoms should be reported to the oncology team.

9. Who should avoid Gros-30?

Paclitaxel may be unsuitable for people with certain severe hypersensitivity histories or significantly abnormal blood counts. The prescribing team also considers liver function, existing medical conditions and previous chemotherapy reactions before treatment. The official labeling includes important restrictions related to severe hypersensitivity and low neutrophil counts.

10. How should Gros-30 be stored?

Gros-30 should be stored and handled according to the manufacturer’s instructions and the requirements for injectable chemotherapy products. It should remain in appropriate medical storage, be protected from unsuitable environmental conditions and not be used after expiry. Preparation and administration should be performed by trained healthcare professionals.

Disclaimer

This Gros-30 Injection information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Paclitaxel is a prescription chemotherapy medicine that can cause serious adverse reactions and must be used under appropriate medical supervision.

Do not self-medicate, attempt to administer Gros-30 yourself, or change the prescribed treatment schedule. Always follow the instructions of your qualified healthcare professional. Individual response, treatment suitability, side effects and outcomes may vary from patient to patient.

This information should not be used to determine a personal Gros-30 dosage or to replace the prescribing information supplied with the product.